Internal Server Error

Aukera - About the company

Aukera is a deadpooled company based in Cambridge (United States), founded in 2009 by Meridith Unger. It operates as a Developing protein therapy for the neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).. The company has 459 active competitors, including 163 funded and 80 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Annexon.

Company Details

Aukera is developing protein therapy for the neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The company has isolated a specific protein called Angeiogenin that may help in slowing symptoms of ALS. Its protein therapy is in the preclinical stage.
Key Metrics
Founded Year
2009
Location
Cambridge, United States
Stage
Deadpooled
Investors
Ranked
Similar Companies
Sign up to download Aukera's company profile

Aukera's funding and investors

Aukera is a funded company. Aukera has 1 institutional investor.

Aukera's founders and board of directors

Founder? Claim Profile
The founders of Aukera is Meridith Unger.
Here are the details of Aukera's key team members:
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Aukera's Competitors and alternates

Top competitors of Aukera include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Aukera, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Denali Therapeutics
Denali Therapeutics
2015, San Francisco (United States), Public
Developer of therapies to treat neurodegenerative diseases
$347M
72/100
2nd
Logo for Fulcrum Therapeutics
Fulcrum Therapeutics
2015, Cambridge (United States), Public
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases
$115M
70/100
3rd
Logo for Annexon
Annexon
2011, San Francisco (United States), Public
Developer of antibodies to treat complement-mediated neurodegenerative diseases
$256M
67/100
4th
Logo for Regenxbio
Regenxbio
2008, Rockville (United States), Public
Developer of AAV Gene Therapy for rare genetic diseases
$108M
67/100
5th
Logo for Alector
Alector
2013, San Francisco (United States), Public
Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders
$215M
65/100
6th
Logo for MeiraGTx
MeiraGTx
2015, New York City (United States), Public
Developer of gene therapies for ocular and neurodegenerative diseases
-
65/100
7th
Logo for Alchemab
Alchemab
2019, London (United Kingdom), Series A
Developer of antibody therapeutics for treating oncology and neurodegenerative conditions
$149M
65/100
8th
Logo for Mission Therapeutics
Mission Therapeutics
2011, Cambridge (United Kingdom), Series D
Developer of small molecule inhibitors targeting specific disease associated enzymes
$192M
64/100
9th
Logo for D&D Pharmatech
D&D Pharmatech
2014, Seongnam-si (South Korea), Public
Developer of GLP-1-based therapeutics for metabolic disease treatment
$205M
64/100
10th
Logo for US World Meds
US World Meds
2001, Louisville (United States), Series B
Developer of therapeutics for the treatment of multiple diseases
$149M
63/100
426th
Logo for Aukera
Aukera
2009, Cambridge (United States), Deadpooled
Developing protein therapy for the neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
-
22/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Aukera's competitors? Click here to see the top ones

Aukera's Investments and acquisitions

Aukera has made no investments or acquisitions yet.

Reports related to Aukera

Here is the latest report on Aukera's sector:

FAQs about Aukera

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford